Theseus Pharmaceuticals Inc (THRX) is trading 9% higher at $8.24 today. The Health Care sector is having a somewhat somber day, this hasn't really affected the stock's share price, as it leaping past other names in the space.

The promising biotech recently reported earnings which were mostly in line with expectations. This would atleast give traders a firm footing to trade around. This doesn't fully explain the strong bullishness on an otherwise dreary day in the markets.

Theseus Pharmaceuticals Inc has been trading between a 52-week high of $24.54 and a 52-week low of $4.86. The stock has a market cap of $319 Million.

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy.

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Seeking Alpha 08-11-22

Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
PR Newswire 08-03-22

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
Benzinga 07-01-22

Theseus Pharmaceuticals initiated with a Buy at H.C. Wainwright
Seeking Alpha 06-30-22

Analysts Predict A Surge In Theseus Pharmaceuticals Inc. (NASDAQ: THRX)?
Stocks Register 06-25-22